logologo

Popular Boards

1 Mentions
Lívia Cristina Ribeiro Teixeira, Marcelo R. Luizon, Karina Braga Gomes | Receptors | (2025)
Primary Link Archive DOI Openalex Full text (OA)

Key Takeaways

Plain English Takeaway

Medicines used for diabetes and weight loss, called GLP-1 receptor agonists, might help protect the brain in Alzheimer’s disease, but more research is needed to know if they really work for memory problems.

Study Aim

This review set out to examine and summarize the current scientific evidence from both laboratory (preclinical) and human (clinical) studies on the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as possible treatments for Alzheimer’s disease (AD). The authors aimed to clarify whether these drugs, which are already used for type 2 diabetes and obesity, could also help slow or prevent brain changes and memory loss in AD by targeting shared disease pathways. Simply put: The paper asks if diabetes drugs called GLP-1RAs could also help treat or prevent Alzheimer’s disease.

Study Design

The authors conducted a comprehensive review of published research, including laboratory studies using cell cultures and animal models of Alzheimer’s disease, as well as clinical trials and observational studies in humans. They examined the effects of several GLP-1RAs—such as dulaglutide, liraglutide, semaglutide, and exenatide—on brain health, memory, and disease markers. The review included both experimental results and data from ongoing and completed clinical trials involving people with or at risk for Alzheimer’s disease. Simply put: The study looked at many past experiments and clinical trials to see how these diabetes drugs affect Alzheimer’s in animals and people.

Findings

The review reports that in laboratory and animal studies, GLP-1RAs often reduced harmful brain changes linked to Alzheimer’s, such as amyloid plaques and tau tangles, and improved memory and brain cell survival. Early clinical studies in people with diabetes showed a lower risk of dementia with GLP-1RA use. Some clinical trials in people with Alzheimer’s found that liraglutide slowed brain shrinkage and cognitive decline, but other trials with exenatide and liraglutide showed little or no effect on memory or disease markers. Ongoing large trials with semaglutide and other GLP-1RAs may provide clearer answers. The authors note challenges, including drug delivery to the brain, side effects, and the need for early treatment. They recommend more research to determine which patients might benefit and when treatment should start. Simply put: Lab studies look promising, but it’s still unclear if these drugs help people with Alzheimer’s, so more research is needed.

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including dulaglutide, liraglutide, semaglutide, and exenatide, are effective treatments for type 2 diabetes mellitus (T2DM) and obesity. These agents mimic the action of the endogenous incretin glucagon-like peptide-1 (GLP-1) by enhancing insulin secretion, inhibiting glucagon release, and promoting weight loss through appetite suppression. GLP-1RAs have recently been suggested to have neuroprotective effects, suggesting their potential as treatment for neurodegenerative disorders, such as Alzheimer’s disease (AD). AD and T2DM share several common pathophysiological mechanisms, including insulin resistance, chronic inflammation, oxidative stress, and mitochondrial dysfunction. These shared mechanisms suggest that therapeutic agents targeting metabolic dysfunction may also be beneficial for neurodegenerative conditions. Preclinical studies on GLP-1RAs in AD models, both in vitro and in vivo, have demonstrated promising neuroprotective effects, including reductions in amyloid-beta accumulation, decreased tau hyperphosphorylation, improved synaptic plasticity, and enhanced neuronal survival. Despite the encouraging results from preclinical models, several challenges need to be addressed before GLP-1RAs can be widely used for AD treatment. Ongoing clinical trials are investigating the potential cognitive benefits of GLP-1RAs in AD patients, aiming to establish their role as a therapeutic option for AD. This review aimed to examine the current literature on preclinical and clinical studies investigating GLP-1 receptor agonists as potential therapeutic agents for AD.

Referenced In

William Fan
21 days ago
Neurodegenerative Diseases and Brain Aging

GLP-1s, Dementia, Alzheimer's, and Type 3 Diabetes

The suite of new GLP-1 agonists (GLP-1RAs) have shown a cascade of fascinating impacts, but the one that I have my eye on is this new idea that GLP-1 drugs may be preventative of brain aging diseases like Alzheimer's and Dementia.

GLP-1 is a naturally produced hormone in the human gut that regulates appetite and insulin secretion. The GLP-1 agonists drugs that have made a splash the last few years like semaglutide (Ozempic/Wegovy), liraglutide (Victoza/Saxenda), and dulaglutide (Trulicity), were originally developed for type 2 diabetes management.

But a 2026 Systematic Review found:

This study contributes to the clinical understanding of GLP-1 RAs and their effect on cognitive dysfunction. Findings from this study indicate GLP-1 RAs as potential therapeutics targeting cognitive function and neurocognitive disorders in persons living with T2DM.

This finding was echoed by a 2025 review which stated:

preclinical evidence has consistently shown the neuroprotective effects of GLP-1RAs, including reduced amyloid and tau pathology, improved synaptic function and enhanced neuronal survival

And a 2025 meta-analysis found that:

(GLP-1RAs) were associated with a statistically significant reduction in dementia

This finding was paired with a null result for the alternative cardio-protective glucose lowering agent sodium-glucose cotransporter-2 inhibitors (SGLT2is), suggesting the the GLP-1RAs are either using a unique pathway or are simply more effective. Contradictorily, a read world study released on the same day found benefits for both GLP-1RAs and SGLT2is; the meta-analysis may have been underpowered to detect SGLTis' benefits.

The link between Alzheimer's or Dementia and Diabetes is well known, with diabetes cited as a major risk factor. This is important to remember when contextualizing these findings as the population for the studies were almost all individuals with Type 2 Diabetes. That means we don't know if these neuroprotective effects can be generalized to people without T2D.

Interestingly as pointed out by the 2025 review, Alzheimer's and Dementia may be thought of as Type 3 Diabetes, as these diseases may be symptoms of underlying insulin dysregulation in the brain and damaged blood vessels. The tie between dementia and cardiovascular health echoes what we've heard in the past, that what's good for the heart is good for the brain. GLP-1 is naturally boosted by exercise and may point to the same correlation we see with exercise and brain health.

Excited to see how these findings pan out over the next few years, GLP-1RAs still require long term trials and reviews against the general population. The results for major trial targeting adults with early onset Alzheimer's released in March 2026 failed to show efficacy of oral semaglutide in reducing Alzheimer's. Note this study was funded by Novo Nordisk.

Oral semaglutide was not efficacious in slowing clinical progression in participants with early Alzheimer's disease.

This could be due to several reasons like the drug being more preventative than capable of reversing symptoms, weaker impacts of older generation GLP-1RAs or effects not being generalized outside of TD2 patients. But this is the strongest clinical result yet and points to the need for more trials before comprehensively marking success.

Read Full Post
1